Literature DB >> 31099972

Developing and testing prognostic bio-scoring systems for canine mammary gland carcinomas.

Karin U Sorenmo1,2, Amy C Durham2,3, Veronica Kristiansen4, Laura Pena5, Michael H Goldschmidt3, Darko Stefanovski6.   

Abstract

Canine mammary carcinomas (CMC) represent a range of histolopathological subtypes with diverse biological behaviours. Several individual factors, including stage, grade, subtypes and presence of invasion, predict outcome. Less is known how these factors interact and impact prognosis. The purpose of this work was to develop and test comprehensive bio-scoring systems in CMCs. Clinical and histopathological data from 127 dogs with MCs treated through two prospective studies were obtained. All dogs underwent standardized pre-surgical staging, treatments and regular follow-up visits. All tumours were evaluated, classified and graded according to published guidelines. Time to primary metastasis was the main endpoint in this study. Two bio-scoring systems were developed: The multivariate scoring (MVS) was based on traditional statistical analysis where only factors significant in the multivariate analysis (tumour size and grade) were kept for the final model. The refined flexible scoring (RFS) system was based on results from subgroup analysis, which guided the development of a flexible system. Progressive worsening prognosis was observed with increasing bio-scores in both systems. MVS: Median primary metastasis-free survival (TTM1 days) was not reached in dogs with bio-scores 0 to 5, 10, 15 and 648, 149, 317, in MVS groups 25, 30, 40, respectively. Similarly, TTM1 was not reached in dogs with RFS 0, 1, 2 and 374, 407 and 149, in dogs with bio-scores 3, 4, 5, respectively. However, a more distinct separation between dogs with high risk vs low risk for metastasis was observed with RFS, suggesting superior overall prognostication regarding the risk for metastasis.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  bio-scoring; dogs; mammary carcinomas; prognosis; prospective studies

Mesh:

Year:  2019        PMID: 31099972     DOI: 10.1111/vco.12509

Source DB:  PubMed          Journal:  Vet Comp Oncol        ISSN: 1476-5810            Impact factor:   2.613


  6 in total

1.  Association of mast cell density, microvascular density and endothelial area with clinicopathological parameters and prognosis in canine mammary gland carcinomas.

Authors:  Simona Sakalauskaitė; Vita Riškevičienė; Jakov Šengaut; Nomeda Juodžiukynienė
Journal:  Acta Vet Scand       Date:  2022-06-27       Impact factor: 2.048

2.  Immune Cells and Immunoglobulin Expression in the Mammary Gland Tumors of Dog.

Authors:  Alessandra Sfacteria; Ettore Napoli; Claudia Rifici; Daria Commisso; Giada Giambrone; Giuseppe Mazzullo; Gabriele Marino
Journal:  Animals (Basel)       Date:  2021-04-21       Impact factor: 2.752

3.  Epidemiological Investigation of Canine Mammary Tumors in Mainland China Between 2017 and 2021.

Authors:  Hui-Hua Zheng; Chong-Tao Du; Chao Yu; Yu-Zhu Zhang; Rong-Lei Huang; Xin-Yue Tang; Guang-Hong Xie
Journal:  Front Vet Sci       Date:  2022-06-22

4.  The estrogen effect; clinical and histopathological evidence of dichotomous influences in dogs with spontaneous mammary carcinomas.

Authors:  Karin U Sorenmo; Amy C Durham; Enrico Radaelli; Veronica Kristiansen; Laura Peña; Michael H Goldschmidt; Darko Stefanovski
Journal:  PLoS One       Date:  2019-10-25       Impact factor: 3.240

5.  Discrimination of Benign and Malignant Lesions in Canine Mammary Tissue Samples Using Raman Spectroscopy: A Pilot Study.

Authors:  Diana Dantas; Liliana Soares; Susana Novais; Rui Vilarinho; J Agostinho Moreira; Susana Silva; Orlando Frazão; Teresa Oliveira; Nuno Leal; Pedro Faísca; Joana Reis
Journal:  Animals (Basel)       Date:  2020-09-14       Impact factor: 2.752

6.  Intratumoral collagen signatures predict clinical outcomes in feline mammary carcinoma.

Authors:  Suzanne Rosen; Becky K Brisson; Amy C Durham; Clare M Munroe; Conor J McNeill; Darko Stefanovski; Karin U Sørenmo; Susan W Volk
Journal:  PLoS One       Date:  2020-08-10       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.